Relay Therapeutics, Inc. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 48/100
What the filing says
Relay Therapeutics amended its at-the-market (ATM) sales agreement with TD Securities on August 6, 2026, increasing the maximum offering size from $250M to $462,978,049 (net $212,978,049 new capacity). The company reported Q2 2026 cash/equivalents/investments of $910.9M (up from $642.1M in Q1 2026, driven by a $316M May 2026 underwritten offering) and projects runway into 2029. Key clinical progress: zovegalisib triplet (plus atirmociclib) selected for Phase 3 first-line breast cancer trial expected early 2027; ReDiscover-2 second-line trial ongoing; ReInspire vascular anomalies trial showed 60% volumetric response at 12 weeks with expansion cohorts opened. Q2 net loss was $83.7M ($0.41/share).
Why this rating
ATM expansion ($212.978M new capacity ≈36% of company market value) is material for a pre-revenue biotech but routine for ongoing capital management. Strong cash position ($911M) reduces near-term dilution risk. Clinical progress in multiple programs is positive but still early-stage (Phase 1/2 and Phase 3 ongoing). No transformational event; normal corporate financing and development execution.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.